Propanc Biopharma, Inc. (PPCB) Plans Q1 2027 Phase 1b PRP Trial; Raises $7.5M, Starts $5M Buyback

Propanc Biopharma reported $7.5M gross proceeds for FY25-26, began a $5.0M share repurchase program, and plans to start a Phase 1b first-in-human PRP study in Q1 2027 enrolling up to 50 advanced solid tumor patients.Material DetailsContext by AI AnalystThis is an early-stage biotech update combinin…